A three-year-old French biopharmaceutical company, Pharnext SAS, has raised €4.8 million in a Series A round to take a new combination drug into the clinic to treat an inherited neurological disorder known as Charcot-Marie-Tooth disease.
UCB SA of Belgium has raised its stake in the German biopharmaceutical company, Wilex AG, to 18.05% from 11.4% following the purchase of a block of shares from a fund managed by Apax Partners. The transaction was reported on 10 June 2010.
Ipsen SA of France will be listed on the over-the-counter market in the US following its agreement with Deutsche Bank to implement a level 1 American Depositary Receipt (ADR) programme. The company’s shares are already listed in Paris.
Sanofi Pasteur has become the second European company in a month to invest in antibody technology in order to discover new treatments for infectious diseases. It is paying €3 million upfront to Vivalis of France for access to the technology.
The French privately-owned immune therapy company, Cytheris SA, has raised €12 million in a Series D financing to accelerate development of its recombinant human interleukin-7 product, CYT107, for cancer and other indications.
Koninklijke Philips Electronics NV of the Netherlands has signed an agreement with the US discovery-stage company, RXi Pharmaceuticals, to explore the use of ultrasound for the delivery RNA interference compounds in cells.
Imperial Innovations Group Plc, a UK technology transfer company, said that it has realised £9.5 million in cash following the sale of its portfolio company, Respivert Ltd, to the Johnson & Johnson subsidiary, Centocor Ortho Biotech Inc.
Noxxon Pharma AG said that it has raised €33 million in a Series D round of financing to support the ongoing clinical and preclinical development of its mirror-image oligonucleotides known as Spiegelmers. The round was led by NGN Capital.
The privately-owned UK pharmaceutical company, Funxional Therapeutics Ltd, has raised €10 million in a Series B funding to advance its lead, small molecule drug candidate into Phase 2 for inflammatory conditions including asthma.
TPP Global Development Plc, a newly formed investor in spin-outs from research institutes and universities, has received a £9.6 million investment from the Scottish Venture Fund and other investors.